Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Benjamin Mendy has bankruptcy case dismissed: Ex
Powerful Hurricane Ida slams U.S. Louisiana, other regions
Lao PM says China taking concrete actions to deepen global anti
WADA defends pick of Swiss prosecutor under scrutiny in review of Chinese swimmers case
China adopts targeted measures to bolster foreign trade growth
China adopts targeted measures to bolster foreign trade growth
Israel celebrates 74th Independence Day
What's causing the catastrophic rainfall in Kenya?
Sky Pool links residential blocks in south London
Democrats vow to protect Speaker Mike Johnson from being ousted from office
U.S. guilty of coercion diplomacy: FM spokesperson